The effects of statins on blood pressure: Current knowledge and future perspectives

Archives of Medical Science

Volumn 8, Issue 1, 2012, Pages 1-3

  Rizzo, Manfredi ^a,b   Montalto, Giuseppe ^a   Banach, Maciej ^c  

^a UNIVERSITY OF PALERMO   (Italy)

^b Euro Mediterranean Institute of Science and Technology   (Italy)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATORVASTATIN; ENDOTHELIN 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; METOPROLOL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SIMVASTATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG EFFECT; DRUG MECHANISM; EDITORIAL; HUMAN; HYPERTENSION; LIPID METABOLISM; NONHUMAN; OXIDATIVE STRESS; PROPHYLAXIS; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE; UPREGULATION;

EID: 84858113693     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2012.27270     Document Type: Editorial

References (25)

1. Curran MP. Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease. Drugs 2010; 70: 191-213.
2. Stepien M, Banach M, Mikhailidis DP, Gluba A, Kjeldsen SE, Rysz J. Role and significance of statins in the treatment of hypertensive patients. Curr Med Res Opin 2009; 25: 1995-2005.
3. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med Sci Monit 2009; 15: MS1-5.
4. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101: 2711-9. (Pubitemid 28294580)
5. Nickenig G, Bäumer AT, Temur Y, Kebben D, Jockenhövel F, Böhm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100: 2131-4.
6. Strazzullo P, D'Elia L, Versiero M. Response to upregulation of nitric oxide, inhibition of oxidative stress, and antihypertensive effects of statins. Hypertension 2007; 49: 792-8.
7. Katsiki N, Mikhailidis DP, Banach M. Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. J Hypertens 2011; 29: 2493-4.
8. Sever PS, Dahlöf B, Poulter NR, et al.; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58. (Pubitemid 36398384)
9. Correa V Jr, Gus M, Fuchs FD. Does the blood pressure-lowering effect of statins contribute to their beneficial cardiovascular effects? Expert Rev Cardiovasc Ther 2010; 8: 775-9.
10. Kostapanos MS, Milionis HJ, Elisaf MS. Current role of statins in the treatment of essential hypertension. Expert Opin Pharmacother 2010; 11: 2635-50.
11. Paynter NP, Sesso HD, Conen D, Otvos JD, Mora S. Lipoprotein subclass abnormalities and incident hypertension in initially healthy women. Clin Chem 2011; 57: 1178-87.
12. Rizzo M, Kotur-Stevuljevic J, Berneis K, et al. Atherogenic dyslipidemia and oxidative stress: a new look. Transl Res 2009; 153: 217-23.
13. Rizzo M, Berneis K, Zeljkovic A, Vekic J. Should we routinely measure low-density and high-density lipoprotein subclasses? Clin Lab 2009; 55: 421-9.
14. Mikhailidis DP, Elisaf MS, Rizzo M, et al. "European Panel on Low Density Lipoprotein (LDL) Subclasses": A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses: Executive Summary. Curr Vasc Pharmacol 2011; 9: 531-2.
15. Mikhailidis DP, Elisaf MS, Rizzo M, et al. "European Panel on Low Density Lipoprotein (LDL) Subclasses": A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses. Curr Vasc Pharmacol 2011; 9: 533-71.
16. Owczarek J, Jasińska M, Wejman I, Kurczewska U, Orszulak-Michalak D. Effects of 4-week administration of simvastatin in different doses on heart rate and blood pressure after metoprolol injection in normocho lesterolaemic and normotensive rats. Arch Med Sci 2012; 8: 17-21.
17. Owczarek J, Jasińska M, Orszulak-Michalak D. Interaction between different doses of simvastatin after two-week administration and metoprolol injection on the heart rate in normocholesterolemic rats. Acta Pol Pharm 2008; 65: 141-5. (Pubitemid 351578442)
18. Owczarek J, Jasińska M, Orszulak-Michalak D. Dose-dependent influence of two-week administration of simvastatin and metoprolol injection on the blood pressure in normocholesterolemic rats. Acta Pol Pharm 2008; 65: 147-51. (Pubitemid 351578443)
19. Karpov RS, Koshel'skaia OA, Suslova TE, Gruzdeva OV, Zhuravleva OA. Effect of 6-month therapy with simvastatin on lipid transport function of the blood and the state of endothelium in patients with diabetes and hypertension [Russian]. Kardiologiia 2006; 46: 27-31. (Pubitemid 44605808)
20. Quinaglia e Silva JC, Munhoz DB, Morato TN, et al.; Brasilia Heart Study Group. Effect of beta blockers (metoprolol or propranolol) on effect of simvastatin in lowering C-reactive protein in acute myocardial infarction. Am J Cardiol 2009; 103: 461-3.
21. Bielecka-Dabrowa A, Aronow WS, Rysz J, Banach M. Current place of beta-blockers in the treatment of hypertension. Curr Vasc Pharmacol 2010; 8: 733-41.
22. Rizzo M, Mikhailidis DP. There is more to predicting vascular disease than just established risk factors. Curr Pharm Des 2011; 17: 3608-10.
23. Tycinska AM, Janica J, Mroczko B, et al. Hypotensive effect of atorvastatin in hypertensive patients: the association among flow-mediated dilation, oxidative stress and endothelial dysfunction. Arch Med Sci 2011; 7: 955-62.
24. Athyros VG, Hatzitolios AI, Karagiannis A, et al. IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci 2011; 7: 984-92.
25. Banach M, Kjeldsen SE, Narkiewicz K. Controversies in hypertension treatment. Curr Vasc Pharmacol 2010; 8: 731-2.